News & Updates
Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) Excerpt from the Press Release: BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer…
Read More
mRNA-1273.222 Targets BA.4/BA.5 Strains of Omicron Variant Pending Authorization, Moderna Ready to Ship Bivalent Booster mRNA-1273.222 in September Clinical Data Available for Moderna’s Bivalent COVID-19 Booster Vaccines Have Met All Primary Endpoints and Support Request for Emergency Use Authorization Excerpt from the Press Release: CAMBRIDGE, MA / ACCESSWIRE / August 23, 2022 / Moderna, Inc.…
Read More
Pegcetacoplan treatment effect accelerated between months 18-24, demonstrating a robust reduction of GA lesion growth compared to sham (all p-values are nominal) DERBY: 36% monthly, p<0.0001; 29% every-other-month (EOM), p=0.0002 OAKS: 24% monthly, p=0.0080; 25% EOM, p=0.0007 Consistent with expectations, no clinically meaningful difference on key functional endpoints observed at 24 months Continued to demonstrate…
Read More
Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure Excerpt from the Press Release: MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced the launch…
Read More
Independent Data Presented at the World Federation of Interventional and Therapeutic Neuroradiology 2022 Annual Meeting Highlights the Benefits of Vessel-Matching with Zoom Reperfusion Catheters Excerpt from the Press Release: CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional…
Read More
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3), patients with cirrhosis also had improved markers of liver injury, glucose metabolism, and lipid metabolism Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022…
Read More
– ADOA is primarily caused by mutations in the OPA1 gene that result in progressive and irreversible vision loss in both eyes starting in the first decade of life – – The FALCON study is designed to evaluate disease progression and its effects on patients – – Data will support clinical development plans for STK-002,…
Read More
The 25-week weight loss study which achieved its previously reported primary endpoints also examined the effects of GS200 on insulin resistance Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of Endocrinology in…
Read More
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ — Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of…
Read More
Excerpt from the Press Release: BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the U.S. Food and Drug Administration (FDA)…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?